Introduction
Obefazimod (Obe) is an oral, once-daily (QD), small molecule that enhances expression of microRNA-124, which restores mucosal immune balance through regulation of Th17 cells and macrophages. Obe has shown efficacy in patients (pts) with moderately to severely active ulcerative colitis (UC) in induction and maintenance trials [1-4]. Here we present efficacy endpoints at week 44 for pts with and without prior inadequate response to advanced therapies (AT-IR-Yes, AT-IR-No) from the ABTECT-Maintenance trial (ABTECT-M, NCT05535946).
Aims & Methods
The phase 3, multicenter, randomized, double-blind, placebo-controlled ABTECT trials enrolled pts with moderately to severely active UC who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors (JAKi). Pts were randomly assigned in a 2:1:1 ratio to receive obefazimod 50 mg (Obe-50), obefazimod 25 mg (Obe-25), or placebo (PBO) for 8 weeks; those who achieved clinical response to Obe were then re-randomized into a 44-week maintenance trial to receive Obe-50, Obe-25, or PBO in a 1:1:1 ratio. Clinical remission per MMS, endoscopic improvement, endoscopic remission, and histo-endoscopic mucosal improvement were analysed at week 44 of ABTECT-M among AT-IR-Yes and AT-IR-No pts; all p-values are nominal.
Results
A total of 1272 pts were randomized and treated in ABTECT induction trials, of which 580 achieved clinical response to Obe induction therapy and entered ABTECT-M. Among pts who participated in ABTECT-M, 41.0% (238/580) were AT-IR-Yes, and 59.0% (342/580) were AT-IR-No. A higher proportion of the AT-IR-Yes subgroup receiving Obe-50 or Obe-25 achieved all efficacy measures relative to PBO at rates that were numerically larger in Obe-50 relative to Obe-25 (Table). In the AT-IR-No subgroup, larger proportions achieved all efficacy measures in patients receiving Obe-50 or Obe-25 relative to PBO at rates that were similar between doses. In the subset of pts who failed JAKi, higher proportion of pts receiving Obe-50 or Obe-25 achieved clinical remission vs PBO. The difference from PBO in clinical remission for Obe-25 and Obe-50 was similar across lines of treatment, from AT-IR-No through 4+ AT-IRs (Table).
Table: 44-week efficacy of obefazimod in patients with and without prior inadequate response* to advanced therapies - ABTECT-Maintenance Phase 3 study
| | ABTECT-M a |
| | AT-IR-Yes | AT-IR-No |
| Efficacy Endpoints at week 44 | PBO (N= 72) | Obe-25 (N= 76) | Obe-50 (N=90) | PBO (N= 120) | Obe-25 (N= 117) | Obe-50 (N=105) |
Clinical remission, % (n) Placebo adjusted Δ % p-value | 6.9 (5) | 34.2 (26) 28.0 p<0.0001 | 42.2 (38) 33.1 p<0.0001 | 12.5 (15) | 61.5 (72) 48.1 p<0.0001 | 59.0 (62) 45.1 p<0.0001 |
Endoscopic improvement, % (n) Placebo adjusted Δ % p-value | 8.3 (6) | 38.2 (29) 31.4 p<0.0001 | 53.3 (48) 42.3 p<0.0001 | 15.0 (18) | 65.8 (77) 51.2 p<0.0001 | 73.3 (77) 57.0 p<0.0001 |
Endoscopic remission, % (n) Placebo adjusted Δ % p-value | 5.6 (4) | 23.7 (18) 17.3 P=0.0049 | 38.9 (35) 31.3 p<0.0001 | 12.5 (15) | 53.0 (62) 41.9 p<0.0001 | 55.2 (58) 42.3 p<0.0001 |
CS-free clinical remission b, % (n) Placebo adjusted Δ % p-value | 5.6 (4) | 30.3 (23) 25.9 p<0.0001 | 37.8 (34) 31.2 p=0.0001 | 12.5 (15) | 54.7 (64) 42.2 p<0.0001 | 56.2 (59) 42.8 p<0.0001 |
Sustained clinical remission c, % (n) Placebo adjusted Δ % p-value | 23.1 (3/13) | 46.7 (7/15) 8.1 p=0.6873 | 56.5 (13/23) 30.0 p=0.0915 | 13.2 (5/38) | 72.4 (42/58) 61.6 p<0.0001 | 71.1 (27/38) 55.3 p<0.0001 |
HEMI, % (n) Placebo adjusted Δ % p-value | 6.9 (5) | 34.2 (26) 26.5 P=0.0002 | 48.9 (44) 39.3 p<0.0001 | 12.5 (15) | 60.7 (71) 48.5 p<0.0001 | 64.8 (68) 51.3 p<0.0001 |
Clinical remission AT-IR pts with JAK failure, % (n/N1**) Placebo adjusted Δ % p-value | 0 (0/16) | 28.6 (4/14) 32.6 p=0.0190 | 33.3 (5/15) 39.2 p=0.0375 | NRI is used for subjects with missing outcome at Week 44 and subjects reporting any IE prior to Week 8 - % Difference is for Obe minus placebo and is based on estimated common risk difference using the Mantel-Haenszel weights adjusting for the randomization stratification factors: clinical remission at maintenance baseline (yes/no), induction treatment (25 mg/50 mg), and maintenance baseline oral corticosteroids usage (yes/no), and region (Japan/rest of world) [ABTECT-2 only]. p-values are two sided. a: all p-values are nominal - Clinical remission: stool frequency sub-score (SFS) ≤1, rectal bleeding sub-score (RBS) = 0 and endoscopic sub-score ≤1; Endoscopic improvement: endoscopic sub-score ≤1; Endoscopic remission: endoscopic sub-score = 0; Histo-endoscopic mucosal improvement (HEMI): combination of histologic improvement (Geboes histologic score ≤3.1) and endoscopic improvement (endoscopy sub-score ≤1); b: CS-free clinical remission is defined as clinical remission (SFS = 0 or 1 and RBS = 0 and MES = 0 or 1 (MES of 1 modified to exclude friability) at Week 44 and corticosteroid free for at least 12 weeks immediately prior to Week 44; c: Sustained clinical remission: clinical remission after maintenance baseline in the sub-population of subjects in clinical remission at Week 8 of the induction study; *: inadequate response = lack of response, loss of response, or intolerance to advanced therapies. **: N1, N2 = total number of pts in the respective subset; JAKi: Janus kinase inhibitor; NC: not calculable. |
Clinical remission AT-IR pts with 1 AT failure, % (n/N2**) Placebo adjusted Δ % p-value | 14.8 (4/27) | 38.7 (12/31) 13.2 p=0.2785 | 41.5 (17/41) 21.6 p=0.0584 |
Clinical remission Pts with 2 AT failure, % (n/N2**) Placebo adjusted Δ % p-value | 0 (0/24) | 31.8 (7/22) 29.2 p=0.0215 | 42.1 (8/19) 47.4 p=0.0014 |
Clinical remission Pts with 3 AT failures, % (n/N2**) Placebo adjusted Δ % p-value | 8.3 (1/12) | 33.3 (4/12) 41.7 p=0.0771 | 47.6 (10/21) 36.4 p=0.0968 |
Clinical remission Pts with 4+ AT failures, % (n/N2**) Placebo adjusted Δ % p-value | 0 (0/9) | 27.3 (3/11) 0.0 NC | 33.3 (3/9) 21.7 p=0.1967 |
Conclusion
Among AT-IR-Yes and AT-IR-No subgroups, improvements in clinical, endoscopic, symptomatic and combined endoscopic-histologic measures were observed in pts treated with Obe at week 44 relative to PBO in the maintenance trial. Improvements vs PBO in clinical remission were observed in AT-IR-Yes JAKi-IR pts and across lines of therapy up to 4+ AT-IR.
References
- Vermeire S, et al. J Crohns Colitis. 2023; 17: 1689-1697
- Vermeire S, et al. The Lancet Gastroenterology & Hepatology. 2022; 7: 1024-1035.
- Vermeire S, et al. J Crohns Colitis. 2025 ; 19 : jjaf074
- Sands BE, et al. UEG Journal, 2025; 13: 1818-1820
Disclosure
BES: Abbvie, Abivax, Adiso Therapeutics, Agomab, Alimentiv, Amgen, AnaptysBio, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Biolojic Design, Biora Therapeutics, Boehringer Ingelheim, BMS, Celltrion, Equillium, Enthera, Enveda Biosciences, Evommune, Ferring, Fzata, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Imhotex, Index Pharmaceuticals, Innovation Pharmaceuticals, Kaleido, Kallyope, Lilly, Merck, Microba, Microbiotica, Mitsubishi Tanabe, Mobius Care, Morphic Therapeutics, MRM Health, Nexus Therapeutics, Nimbus Discovery, Odyssey Therapeutics, OSE Immunotherapeutics, Janssen, Palisade Bio, Pfizer, Protagonist Therapeutics, Q32 Bio, Rasayana Therapeutics, Recludix Therapeutics, Reistone Biopharma, Sanofi, Sorriso Therapeutics, Spyre Therapeutics, Takeda, Target RWE, Teva, TLL Pharmaceutical, Tr1X, Trex Bio, Union Therapeutics, Ventyx Biosciences; SV: AbbVie, Abivax, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma; SD: AbbVie, Ferring, Hospira, J&J, Merck, MSD, Takeda, Mundipharma, Pfizer, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim; LPB: Abbvie, Abivax, Adacyte, Alimentiv, Amgen, Applied Molecular Transport, Arena, Banook, Biogen, BMS, Celltrion, Connect Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, IAC Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Pandion Therapeuthics, Par' Immune, Pfizer, Prometheus, Protagonist, Roche, Samsung, Sandoz, Sanofi, Satisfay, Takeda, Telavant, Theravance, Thermo Fischer, Tigenix, Tillots, Viatris, Vectivbio, Ventyx, Ysopia; HT: Abbvie, Abivax, Dr Falk Pharma, Ferring, Galapagos, Microbiotica, MSD, Pfizer, Takeda ; US: AbbVie, Abivax, Amgen, Galapagos, Janssen, Lilly ; DR: Abbvie, Abivax, Altrubio, Athos Therapeutics, BMS, Celltrion, Connect BioPharma, Eli Lilly, Genentech, Iterative Health, Janssen, J&J, Merck, Odyssey Therapeutics, Pfizer, Sanofi, Spyre, Takeda, Vedanta Biosciences, Ventyx ; PSD : Abbvie, Abivax, Adiso, Alimentiv, BMS, Celltrion, Genentech, Geneoscopy, Janssen, Pfizer, Takeda ; MD : Abbvie, Abivax, Arena, AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Hoffmann-La-Roche, Genentech, Gilead, Janssen, Merck, Pfizer, Prometheus Biosciences, Takeda; BS: AbbVie, AltruBio, Abivax, Boehringer Ingelheim, BMS, Dr. Falk Pharma, Eli Lilly, Endpoint Health, Falk, Galapagos, Gilead, Janssen, Landos, Materia Prima, PredictImmune, Pfizer, and Takeda; TH: Mitsubishi Tanabe Pharma Corporation, EA pharma Co., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer, Eli Lilly, Gilead Sciences, BMS, Abivax ; XT : Celltrion, AbbVie, J&J, Lilly, Takeda, Alpha Sigma, Dr. Falk, Abivax, Biogen, Fresenius Kabi, MSD, Pfizer, Tillotts, and Thabor Therapeutics ; RA : AbbVie, Abivax, AstraZeneca, BMS, Celltrion Healthcare, Galapagos, J&J, Lilly, MSD, Pfizer, Takeda; AA: AbbVie, Abivax, Alfa Sigma, Astra Zeneca, Biogen, Boehringer Ingelheim, BMS, Celltrion, Eli-Lilly, Enthera, Ferring, Galapagos, Gilead, Giuliani, Janssen, Lionhealth, MSD, Nestlé, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sanofi, Sandoz, Takeda, Teva Pharmaceuticals, Tillots Pharma; FB: AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Celltrion, Ferring, Fresenius Kabi, J&J, Merck Sharp & Dohme, Pfizer Inc, and Sandoz; GDH : Abbvie, Abivax, Agomab, Alimentiv, Anaptys Bio, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Galapagos, Glaxo Smith Kline, Dr Falk Pharma, Pfizer, J&J, Merck, Mirador, Polpharma, Procise Diagnostics, Prometheus Biosciences, Sorriso Pharma, Spyre, Takeda, Ventyx